UCB SA (EBR:UCB)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 47.51B |
| Revenue (ttm) | 7.74B |
| Net Income (ttm) | 1.56B |
| Shares Out | 190.36M |
| EPS (ttm) | 8.03 |
| PE Ratio | 31.08 |
| Forward PE | 23.72 |
| Dividend | 1.45 (0.57%) |
| Ex-Dividend Date | Apr 25, 2025 |
| Volume | 267,111 |
| Average Volume | 247,855 |
| Open | 244.60 |
| Previous Close | 252.30 |
| Day's Range | 242.00 - 254.10 |
| 52-Week Range | 129.35 - 289.50 |
| Beta | 0.27 |
| RSI | 37.78 |
| Earnings Date | Feb 26, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial StatementsNews
UCB SA (UCBJY) Q4 2025 Earnings Call Transcript
UCB SA (UCBJY) Q4 2025 Earnings Call Transcript
UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...
UCB SA (UCBJF) Q2 2025 Earnings Call Transcript
UCB SA (OTCPK:UCBJF) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Antje Witte - Head of Investor Relations Emmanuel Caeymaex - Executive VP & Chief Commercial Officer...
Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy
UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for psoriasis an...
UCB SA (UCBJF) Q2 2024 Earnings Call Transcript
UCB SA (OTCPK:UCBJF) Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Antje Witte - Head, IR Jean-Christophe Tellier - CEO Sandrine Dufour - CFO Emmanuel Caeymaex - CCO I...
UCB SA (UCBJF) Full Year 2023 Earnings Call Transcript
UCB SA (OTCPK:UCBJF) Full Year 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Antje Witte – Investor Relations Jean-Christophe Tellier – Chief Executive Officer Emmanu...